Clear Strategies for Growth
The Company's B.E.S.T. Platform™ utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.
The importance of biomarkers for common cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society.
Discovery
- Disease indication and test utility are selected
- Research study is initiated; samples are collected and analyzed
- Discovery of biomarker candidates with varying levels of expression within normal and diseased states
- Initial sensitivity and specificity (diagnostic test performance) of panel of individual biomarkers is established
- Use patent applications are filed
Validation
- Collection of additional samples provides a naive sample set for analysis
- Consistent expression of biomarker candidates is confirmed
- Sensitivity and specificity is verified
Protein identification
- Target proteins are purified
- Proteins biomarkers are identified using multiple, complementary approaches
- Patent position is updated
Immunoassay development
- ELISA-based test format that will meet clinical laboratory testing standards is developed
- Sensitivity and specificity of the diagnostic test is refined and finalized
Commercialization
- Partnerships are developed to manufacture and commercialize the product